Table 2: Differences in miRNA expression in PTC patients with different clinicopathological features.

Clinicopathologic
features
miRNA-221miRNA-222miRNA-146bmiRNA-181miRNA-21
2−ΔΔCt 2−ΔΔCt 2−ΔΔCt 2−ΔΔCt 2−ΔΔCt

Sex
 Male9.03
(0.73–269.35)
0.6947.56
(0.75–58.31)
0.739129.37
(0.72–552.00)
0.4255.58
(0.57–12.55)
0.57910.86
(1.23−38.03)
0.461
 Female8.99
(0.68–212.90)
8.24
(0.04–168.94)
104.69
(1.28–2917.96)
3.15
(0.09–80.72)
7.70
(0.06−168.32)
Age
 <45 years8.82
(0.68–212.90)
0.6937.55
(0.04–168.94)
0.137103.97
(0.72–2917.96)
0.7353.38
(0.49–80.72)
0.7497.07
(1.23−168.32)
0.585
 ≥45 years9.29
(0.73–269.35)
13.03
(0.81–58.31)
138.19
(2.36–1123.18)
2.95
(0.09–12.55)
8.32
(0.06−28.83)
Size
 <2 cm7.19
(0.73–212.90)
0.0047.56
(0.75–168.94)
0.24482.08
(0.72–2917.96)
0.0882.99
(0.09–80.72)
0.0086.96
(0.06−168.32)
0.143
 ≥2 cm15.60
(0.68–269.35)
10.70
(0.04–58.31)
150.07
(1.28–1123.18)
5.58
(1.21–18.86)
11.24
(1.42−35.14)
TNM stage
 I/II8.41
(0.68–212.90)
0.0417.30
(0.04–168.94)
0.00492.70
(0.72–2917.96)
0.2863.12
(0.49–80.72)
0.2867.26
(1.23−168.32)
0.157
 III/IV21.44
(2.70–269.35)
28.51
(2.73–58.31)
183.96
(5.00–278.56)
4.80
(0.09–12.55)
15.05
(0.06−27.56)
LN metastasis
 No6.68
(0.73–212.90)
0.0334.54
(0.75–22.92)
0.01482.15
(0.72–2917.96)
0.250 2.36
(0.57–80.72)
0.1037.17
(1.23−168.32)
0.423
 Yes14.43
(0.68–269.35)
11.82
(0.04–168.94)
129.37
(1.28–1123.18)
4.35
(0.09–18.86)
9.82
(0.06–28.83)
BRAF mutation
 No6.36
(0.68–269.35)
0.0014.73
(0.04–168.94)
0.01955.11
(0.72–2917.96)
0.0032.46
(0.09–80.72)
0.0056.81
(0.06–168.32)
0.104
 Yes15.29
(2.70–62.02)
11.82
(2.73–43.93)
182.19
(10.70–1123.18)
5.58
(2.08–18.86)
10.86
(1.44–28.83)
Heteromorphic nucleus
 No9.16
(0.68–269.35)
0.81910.39
(0.04–168.94)
0.302118.72
(0.72–2917.96)
0.2403.38
(0.09–80.72)
0.7978.32
(0.06–168.32)
0.548
 Yes8.82
(0.86–18.00)
6.13
(1.94–8.24)
49.69
(6.77–144.74)
3.12
(0.49-9.49)
5.46
(1.44-39.03)
Multicentricity
 No8.33
(0.73–212.90)
0.8077.94
(0.75–168.94)
0.94092.67
(0.72–2917.96)
0.8073.26
(0.49–0.72)
0.8669.00
(1.23–168.32)
0.275
 Yes10.01
(0.68–269.35)
7.63
(0.04–58.31)
118.72
(1.28–313.67)
3.23
(0.09–18.86)
7.07
(0.06–35.14)
AMES
 Low8.99
(0.68–212.90)
0.3417.65
(0.04–168.94)
0.2038 0.8623.15
(0.09–80.72)
0.2667.60
(0.06–168.32)
0.583
 High22.82
(0.73–269.35)
37.91
(1.67–58.31)
150.07
(2.36–278.56)
5.59
(0.57–12.55)
8.75
(1.30–27.40)
Thyroglobulin level
 Low7.67
(0.68–21.50)
0.22512.23
(0.82–13.37)
0.626205.95
(1.28–208.88)
0.4272.46
(1.21–4.35)
0.99317.55
(1.42–27.56)
0.407
 Normal8.17
(0.73–212.90)
7.65
(0.04–168.94)
103.26
(0.72–2917.96)
3.15
(0.09–80.72)
7.17
(0.06–168.32)
 High13.01
(1.14–269.35)
10.82
(0.81–58.31)
136.74
(6.75–1123.18)
3.44
(0.79–12.55)
8.89
(3.91–28.83)

The data are shown as median (range); value was determined by the Mann-Whitney U test.
TNM: tumor node metastasis; LN: lymph nodes; AMES: age, metastasis to distant sites, extrathyroidal invasion, and tumor size scoring system.